Adenocarcinoma to SCC lineage transformation is the least common type of acquired resistance to EGFR TKIs, although the incidence of SCC transformation during first-line osimertinib therapy might be higher than previously seen with later-line osimertinib or earlier-generation EGFR TKIs [18,66]. This evidence concerns the gene EGFR and adenocarcinoma.